Crescent Biopharma

IPO

Transform the Paradigm

Public · $211.0M raised

Business Model
B2B
Total Funding
$211.0M
Last Round
$200.0M Private EquityOct 2024
Rounds
2
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Crescent Biopharma is a clinical-stage oncology company focused on delivering next-generation therapies for people with cancer. Its pipeline includes CR-001 (a PD-1 x VEGF bispecific), CR-002 (a PD-L1 antibody-drug conjugate), and CR-003 (an ITGB6 antibody-drug conjugate), targeting recent breakthroughs in immuno-oncology and improved, tumor-targeting chemotherapy delivery. The company is led by CEO Joshua Brumm and a leadership team with prior experience at Dyne Therapeutics, Pharmacyclics, and other oncology companies, and is headquartered in Waltham, Massachusetts.

Summary

Crescent Biopharma is a Biotech company. It has raised $211.0M in total across 2 rounds, most recently a $200.0M Private Equity round in Oct 2024. Investors include Fairmount and Venrock.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Private EquityPrivate EquityOct 2024
$200.0M

Sign up to see all 2 events

Funding: Seed through Private Equity. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Crescent Biopharma on Indexed.vc
<a href="https://indexed.vc/companies/crescent-biopharma"><img src="https://indexed.vc/api/badge/company/crescent-biopharma" alt="Crescent Biopharma on Indexed.vc" width="260" height="76" /></a>